(Approval lapsed) TNKASE tenecteplase 50mg powder for solution kit (USA)
Section 19A approved medicine
(Approval lapsed) TNKASE tenecteplase 50mg powder for solution kit (USA)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN: 20605457430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
METALYSE tenecteplase (rch) 50mg powder for injection vial plus prefilled syringe - ARTG 75013
Indication(s)
Indicated for the thrombolytic treatment of the acute phase of myocardial infarction.
Treatment should be initiated as soon as possible after the onset of symptoms.
Treatment can be initiated within 12 hours of symptom onset.
Images
